A Non-interventional Study of the Time to Relapse of Iron Deficiency Anaemia After Standard Treatment With the Intravenous Iron Monofer (10% Iron Isomaltoside 1000)

Trial Profile

A Non-interventional Study of the Time to Relapse of Iron Deficiency Anaemia After Standard Treatment With the Intravenous Iron Monofer (10% Iron Isomaltoside 1000)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 20 Jun 2017

At a glance

  • Drugs Iron isomaltoside 1000 (Primary)
  • Indications Iron deficiency anaemia
  • Focus Therapeutic Use
  • Acronyms CHIL 5269
  • Sponsors Pharmacosmos
  • Most Recent Events

    • 13 Jun 2017 Planned number of patients changed from 200 to 350.
    • 13 Jun 2017 Planned End Date changed from 1 Jan 2018 to 1 Dec 2018.
    • 13 Jun 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top